STERIS plc STE
208.93
0.16
0.08%
as of 25 Sep
- Market cap
- $20.4B
- P/E
- 25.4×
Follow STE
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
STERIS plc (STE) EBITDA
STERIS plc's EBITDA for fiscal 2026 was $1.6B, up 18.3% from $1.3B in fiscal 2025. Over the twelve months to 30 June 2026 it was $1.6B. Over the past ten years it has ranged from $318.8M (fiscal 2015) to $1.6B (fiscal 2026) — the current reading is the highest in ten years. STERIS plc ranks 9th of 147 Medical Devices companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2026 | $1.6B | 18.28% |
| FY2025 | $1.3B | (4.50%) |
| FY2024 | $1.4B | 4.05% |
| FY2023 | $1.4B | 23.12% |
| FY2022 | $1.1B | 42.99% |
| FY2021 | $767.6M | 4.54% |
| FY2020 | $734.3M | 15.28% |
| FY2019 | $636.9M | 10.16% |
| FY2018 | $578.2M | 22.32% |
| FY2017 | $472.7M | 32.53% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $409.7M | (6.91%) |
| Mar 2026 | $440.1M | 11.33% |
| Dec 2025 | $395.3M | 2.01% |
| Sep 2025 | $387.5M | 6.05% |
| 42 more quarters | Free account |
Against its own ten years
Low $318.8M
High $1.6B
Ten-year median
$750.9M
Current reading's percentile
100
EBITDA against peers
| Company | EBITDA |
|---|---|
| PHG Koninklijke Philips N.V. compare | $3.4B |
| GEHC GE HealthCare Technologies Inc. compare | $3.3B |
| SNN Smith & Nephew SNATS, Inc. compare | $2.6B |
| ZBH Zimmer Biomet Holdings, Inc. compare | $2.3B |
| STE STERIS plc | $1.6B |
| DXCM DexCom, Inc. compare | $1.4B |
| PEN Penumbra, Inc. compare | $204.5M |
| BIO Bio-Rad Laboratories, Inc. compare | $53.1M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $53.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on STE
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement